You are here

Blood Adv DOI:10.1182/bloodadvances.2018020396

A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML.

Publication TypeJournal Article
Year of Publication2018
AuthorsGopal, S, Lu, Q, Man, JJ, Baur, W, Rao, SP, Litichevskiy, L, Papanastasiou, M, Creech, AL, DeRuff, KC, Mullahoo, J, Officer, A, Egri, SB, Davison, D, Jaffe, JD, Jaffe, IZ
JournalBlood Adv
Volume2
Issue14
Pages1680-1684
Date Published2018 Jul 24
ISSN2473-9537
DOI10.1182/bloodadvances.2018020396
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/30021779?dopt=Abstract

Alternate JournalBlood Adv
PubMed ID30021779
PubMed Central IDPMC6058230
Grant ListU54 HG008097 / HG / NHGRI NIH HHS / United States